Protalix BioTherapeutics, Inc.
PLX
$1.40
$0.032.19%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -155.73% | 100.68% | 246.89% | 52.06% | 23.97% |
| Total Depreciation and Amortization | 3.59% | 1.52% | 3.13% | -0.93% | 2.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.98% | -72.45% | 419.72% | 13.00% | -74.75% |
| Change in Net Operating Assets | 46.62% | -105.91% | 22.21% | -126.62% | 3.99% |
| Cash from Operations | -226.74% | -2.78% | 213.71% | -186.20% | 16.50% |
| Capital Expenditure | 28.00% | -388.51% | 49.42% | 71.24% | -139.20% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.96% | -172.98% | 255,237.50% | 0.00% | 91.30% |
| Cash from Investing | 97.96% | -175.37% | 11,392.78% | 70.30% | -77.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 39.99% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 39.99% | 117.76% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -114.81% | 2,800.00% | 90.00% | -185.71% | 74.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.05% | -290.75% | 205.25% | -206.57% | 10.82% |